Kemi Olugemo is a Neuroscience Researcher and Healthcare Advocate. Over her two decades in clinical research and practice, Kemi has been involved in all phases of drug development and global medical strategy. Kemi draws on a diverse set of experiences, including being the current Director of Communications at Women of Color in Pharma (WOCIP), serving on the Scientific Committee of the International Society for CNS Clinical Trials and Methodology (ISCTM), and founding a healthcare nonprofit organization called Zebulon Foundation, Inc.
Twitter 
Linked In 
Some view the COVID-19 pandemic as a reputational turning point for pharma and an opportunity to solidify a more positive impact on society. Many pharmaceutical companies are furthering this goal by incorporating ESG into their operations.
The United States continues to face a growing obesity epidemic. The number of people living with excess weight has tripled since 1975, standing at 39% of the American population. Carrying extra pounds is linked with lifelong illnesses such as cardiovascular disease, diabetes, and cancer.
